The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine - PubMed (original) (raw)

Review

The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine

Sophie A Valkenburg et al. Front Immunol. 2018.

Abstract

Influenza viruses circulate worldwide causing annual epidemics that have a substantial impact on public health. This is despite vaccines being in use for over 70 years and currently being administered to around 500 million people each year. Improvements in vaccine design are needed to increase the strength, breadth, and duration of immunity against diverse strains that circulate during regular epidemics, occasional pandemics, and from animal reservoirs. Universal vaccine strategies that target more conserved regions of the virus, such as the hemagglutinin (HA)-stalk, or recruit other cellular responses, such as T cells and NK cells, have the potential to provide broader immunity. Many pre-pandemic vaccines in clinical development do not utilize new vaccine platforms but use "tried and true" recombinant HA protein or inactivated virus strategies despite substantial leaps in fundamental research on universal vaccines. Significant hurdles exist for universal vaccine development from bench to bedside, so that promising preclinical data is not yet translating to human clinical trials. Few studies have assessed immune correlates derived from asymptomatic influenza virus infections, due to the scale of a study required to identity these cases. The realization and implementation of a universal influenza vaccine requires identification and standardization of set points of protective immune correlates, and consideration of dosage schedule to maximize vaccine uptake.

Keywords: T cell; clinical trials; hemagglutinin-stalk; influenza virus; universal vaccine.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Pubmed indexed publication trend for universal influenza vaccines.

References

    1. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis (2006) 12(1):73–7. 10.3201/eid1201.050983 -DOI -PMC -PubMed
    1. Hayward AC, Wang L, Goonetilleke N, Fragaszy EB, Bermingham A, Copas A, et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med (2015) 191(12):1422–31. 10.1164/rccm.201411-1988OC -DOI -PMC -PubMed
    1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine (2007) 25(27):5086–96. 10.1016/j.vaccine.2007.03.046 -DOI -PubMed
    1. Palache A, Abelin A, Hollingsworth R, Cracknell W, Jacobs C, Tsai T, et al. Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004-2015): the 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness. Vaccine (2017) 35(36):4681–6. 10.1016/j.vaccine.2017.07.053 -DOI -PubMed
    1. Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev (2013) 26(3):476–92. 10.1128/CMR.00097-12 -DOI -PMC -PubMed

Publication types

LinkOut - more resources